CONMED Corporation delivered a quietly constructive second quarter of fiscal 2026, with reported net sales advancing modestly and adjusted diluted earnings per share climbing twenty percent. Stripped of the gastroenterology product line that management exited during the half, organic constant currency growth reached a mid-single-digit pace, and AirSeal, Buffalo Filter, and BioBrace each contributed to a sharp expansion in gross margin. The quarter also reset the balance sheet, as the issuer repurchased the bulk of its convertible notes and funded the transaction through a new senior term loan and incremental revolver borrowings. The reshaped portfolio, leadership additions, and updated full-year guidance color the investment thesis in a way that the headline GAAP figures do not.
Management raised and tightened its 2026 outlook, with net sales now guided higher and adjusted earnings per share guided well above the prior range. Two new independent directors joined the board in July, a permanent Chief Financial Officer was appointed, and AirSeal received an expanded indication covering the latest-generation robotic surgery platform. Trading mid-range within its fifty-two week band, the equity sits at an attractive forward earnings multiple against the updated guidance. The combination of disciplined portfolio surgery, a margin-positive mix shift, a cleaner balance sheet, and a fresh executive team shapes a setup that rewards patient capital.
Risks remain, including variable-rate exposure, competitive pressure in electrosurgery, lingering tariff and supply-chain volatility, and a residual convertible maturity scheduled for mid-2027. Even so, the underlying earnings power is more focused than at any point in recent history, and management's near-term commentary signals confidence in the revised trajectory. The combination of organic constant currency growth, mix-driven margin expansion, and disciplined capital allocation creates an attractive twelve-month setup for investors who can underwrite the optimization savings realization and the AirSeal adoption cadence.